These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

51 related items for PubMed ID: 4964378

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers.
    Durbin AP, Whitehead SS, McArthur J, Perreault JR, Blaney JE, Thumar B, Murphy BR, Karron RA.
    J Infect Dis; 2005 Mar 01; 191(5):710-8. PubMed ID: 15688284
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine.
    Guy B, Chanthavanich P, Gimenez S, Sirivichayakul C, Sabchareon A, Begue S, Yoksan S, Luxemburger C, Lang J.
    Vaccine; 2004 Sep 09; 22(27-28):3563-74. PubMed ID: 15315835
    [Abstract] [Full Text] [Related]

  • 9. Immuno-biological studies on dengue. I. Immunogenic effects of partially purified dengue-1 virus and some of its components.
    Fujita N, Tamura M, Hotta S.
    Kobe J Med Sci; 1976 Sep 09; 22(3):211-28. PubMed ID: 828685
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF.
    Raviprakash K, Marques E, Ewing D, Lu Y, Phillips I, Porter KR, Kochel TJ, August TJ, Hayes CG, Murphy GS.
    Virology; 2001 Nov 10; 290(1):74-82. PubMed ID: 11883007
    [Abstract] [Full Text] [Related]

  • 13. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults.
    Kitchener S, Nissen M, Nasveld P, Forrat R, Yoksan S, Lang J, Saluzzo JF.
    Vaccine; 2006 Feb 27; 24(9):1238-41. PubMed ID: 16213632
    [Abstract] [Full Text] [Related]

  • 14. [Future prospects in developing of dengue vaccines].
    Valero N, Levy A.
    Invest Clin; 2008 Jun 27; 49(2):135-8. PubMed ID: 18717261
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children.
    Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, Sirivichayakul C, Pengsaa K, Pojjaroen-Anant C, Chambonneau L, Saluzzo JF, Bhamarapravati N.
    Pediatr Infect Dis J; 2004 Feb 27; 23(2):99-109. PubMed ID: 14872173
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Dengue-3 (16562) PGMK 33 vaccine: neurovirulence, viremia and immune responses in Macaca fascicularis.
    Angsubhakorn S, Yoksan S, Pradermwong A, Nitatpattana N, Sahaphong S, Bhamarapravati N.
    Southeast Asian J Trop Med Public Health; 1994 Sep 27; 25(3):554-9. PubMed ID: 7777925
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.